ImmunityBio, Inc.IBRX

Market cap
$2.3B
P/E ratio
Dec 31,
2015
Dec 31,
2016
Dec 31,
2017
Dec 31,
2018
Dec 31,
2019
Dec 31,
2020
Dec 31,
2021
Dec 31,
2022
Net loss----96-66-92-350-417
Stock-based compensation expense211743723325740
Fair Value Adjustment of Warrants1-------13
Transaction Costs, Warrant Liability-------1
Depreciation and amortization14610991418
Non-cash interest items, net (including amounts with related parties)-----0-12-12
Amortization of related-party notes discounts-------16
Operating Lease, Right-of-Use Asset, Amortization Expense-------6
Amortization of premiums, net of discounts, on marketable debt securities0-2-2-0--1--1
Unrealized losses (gains) on equity securities-------5-4
Unrealized loss on non-marketable equity investment-----1--
Impairment of intangible assets-------1
Impairment of fixed assets-------1
Deferred tax-0-1-0-0---0-0
Other------00
Prepaid expenses and other current assets3--010-91217
Investment and other assets1-0-01404-2
Accounts payable-------48
Accrued expenses and other liabilities22-013-12454
Related parties-------10-1
Operating lease liabilities------4-4-4
Net cash used in operating activities----63-61-70-274-337
Purchases of property, plant and equipment273513433478
Purchase of intangible assets-------21
Proceeds from sales of property, plant and equipment---0--20-
Purchases of marketable debt securities, available-for-sale198273111---14234
Maturities of marketable debt securities, available for sale-----6556128
Proceeds from Sale and Maturity of Marketable Securities27166254165112-1434
Investment in joint venture – an equity method investment-------1
Net cash provided by (used in) investing activities---5721-21-8527
Proceeds from Related Party Debt------339174
Proceeds from Issuance of Common Stock-----8616560
Proceeds from Stock Options Exercised111--150
Proceeds from Contributions from Affiliates------1-
Net share settlement for RSUs vesting21100141
Principal payments of finance leases-------0
Payment for contingent consideration------00
Net cash provided by financing activities----13987505234
Effect of exchange rate changes on cash, cash equivalents, and restricted cash------00
Net change in cash, cash equivalents, and restricted cash------146-76
Interest-01000235
Income taxes00000000
Gain on extinguishment of debt with related parties under common control-------83
Debt Conversion, Converted Instrument, Amount----1--52
Issuance Of Warrants-------35
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability-----52315
Capital Expenditures Incurred but Not yet Paid----001213
Stock Issued----01111
Right-of-Use Asset Obtained in Exchange for Finance Lease Liability-------0
Unrealized Gain (Loss) on Investments0-0-000-0-0-0
Accrued investment in joint venture------1-